Skip To Main Content

Science at Sanofi

Discover a wide variety of articles, videos, podcasts, accredited courses, applications, conferences and scientific events in different therapeutic areas.

Sort by

Filters

Reset
  • Therapeutical Areas
  • Type of Content

Thank You!

The End

What has been your experience with switching patients from alglucosidase alfa to avalglucosidase alfa?

Current Treatment Landscape & hands on Experience

Pompe Care Podcast Series 2

What makes avalglucosidase alfa different from alglucosidase alfa in terms of clinical efficacy and patient outcomes?

Advances in Therapy: Avalglucosidase Alfa & Future Innovations

How can you see changing the lives of patient starting taking Nexviazyme and if you can share from your experience couple of patient stories that realy impacted positively from staring the treatment for Pompe disease?

From your experience

Structured Monitoring for Early Detection of Fabry Progression

Renal Outcomes After Switching to Agalsidase Beta: A Single-Center Analysis

Dupilumab for Patients with AFRS

When the Heart, Kidneys, and Nerves Intersect

Differentail Diagnosis for Patient with Unexplained Neuropathic Pain, Unknown LVH, or Dialysis Requirements. Dr. Khalid Naji

The Pathophysiology of Prurigo Nodularis

Importance of Therapeutic Management of Quality of Life among Patients with Atopic Disorders

Fabry Disease in Cardiology Practice: From Red Flags to Diagnosis